Abstract:Thyroid stimulating hormone（TSH）suppression therapy is a long - term and persistent systemic treatment strategy for patients with differentiated thyroid carcinoma（DTC）after surgery. Adjuvant TSH suppression therapy after surgery can effectively reduce the risk of postoperative recurrence of thyroid cancer，delay disease progression，and improve long- term survival. However， TSH suppression therapy has certain side effects such as inducing or exacerbating cardiovascular disease and osteoporosis. Balancing the risk of recurrence and side effects and dynamically adjusting treatment plans are the important goals and essence of postoperative follow-up treatment for DTC. This article summarizes the consensus of relevant guidelines on the staging，medication selection，side effect monitoring，and prevention of postoperative TSH suppression therapy for DTC patients after surgery. And it improves the TSH suppression therapy guidelines and dual risk assessment system for postoperative patients， in order to promote the further standardization of clinical systematic treatment for DTC patients after surgery.